New combo therapy targets liver metastases in hard-to-treat cancers
NCT ID NCT04701476
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a drug directly to tumors with pembrolizumab, an immunotherapy that helps the immune system fight cancer. The goal is to see if this combination can shrink tumors and help people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER; LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hsinchu Hospital
RECRUITINGHsinchu, Taiwan
Contact Email: •••••@•••••
-
Chung Shan Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Email: •••••@•••••
-
University of California, Irvine Medical Center
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.